PMID: 7037150Feb 1, 1982Paper

Autologous bone marrow rescue in the treatment of advanced tumors of childhood

Cancer
H EkertG P Tauro

Abstract

High-dose multiagent chemotherapy followed by autologous marrow rescue was used in the treatment of 13 patients with Stage III or IV childhood tumors. Encouraging results are being obtained in abdominal lymphoma (1/3 complete remissions (CR); rhabdomyosarcoma (2/4 CR); and retinoblastoma (1/2 CR). In neuroblastoma, the results are disappointing, with only one of four patients in CR; this patient developed a lymphoma associated with Epstein-Barr virus infection. Marrow reconstitution was obtained in 11 patients, with recovery of neutrophils to greater than 0.5 x 10(9)/liter between six and 30 days and platelet recovery to greater than 50 x 10(9)/liter between seven and 38 days. Investigations on the numbers of cells or committed granulocyte precursors ()CFU-c's) infused and parameters of hematologic recovery show poor correlation and suggest that a more accurate and reliable assay for the predictability of cryopreserved marrow to reconstitute marrow function within a reasonable time is necessary. Nonhematologic toxicities of high-dose multiagent chemotherapy are the principal dose-limiting factors.

References

Mar 29, 1977·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J S TobiasR A Yankee
Jan 1, 1979·Gut·T A Miller, E D Jacobson
Jan 1, 1980·Medical and Pediatric Oncology·H EkertK Tiedemann

❮ Previous
Next ❯

Citations

Jan 1, 1982·Cancer Chemotherapy and Pharmacology·S B Kaye
Mar 29, 2001·Survey of Ophthalmology·M W WilsonB G Haik
May 2, 2001·Proceedings of the National Academy of Sciences of the United States of America·R S ArnoldJ D Lambeth
Dec 1, 1986·The Journal of Clinical Investigation·B P AlterD G Nathan
May 1, 1995·Medical and Pediatric Oncology·L White
Mar 1, 1984·Mayo Clinic Proceedings·R P Kadota, W A Smithson
Feb 1, 1986·Clinics in Haematology·C R Singer, A H Goldstone
Feb 1, 1986·Clinics in Haematology·R PinkertonJ Kemshead
Jun 1, 1983·Pediatric Annals·C Lenarsky, S A Feig
Feb 1, 1990·Journal of Pediatric Surgery·M P LaQuagliaP R Exelby
Jul 1, 1986·European Journal of Cancer & Clinical Oncology·J O ArmitageK A Dicke
Jun 1, 1987·Australian and New Zealand Journal of Medicine·W P SheridanG Morstyn
Mar 1, 1984·International Journal of Cell Cloning·W M EllisK E Rendall
Jun 15, 1986·International Journal of Cancer. Journal International Du Cancer·D A Worthington-WhiteC M Riley
May 2, 2002·Medical and Pediatric Oncology·A Y N Schouten-Van MeeterenA J P Veerman
Sep 15, 1984·Cancer·G SpitzerE J Freireich
Jan 1, 1990·Pediatric Hematology and Oncology·I YanivT Philip

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.